Biocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Novo Nordisk says the decision was made based on “Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make ...

Drugmaker Novo Nordisk said it is halting its agreement with telehealth company Hims & Hers after less than two months, ...

Novo Nordisk said it will stop selling Wegovy on ... in knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China and that a large ...